New combo therapy aims to shrink rectal tumors before surgery
NCT ID NCT07381400
First seen Feb 02, 2026 · Last updated May 17, 2026 · Updated 19 times
Summary
This study tests whether adding an immunotherapy drug (Serplulimab) to standard chemotherapy before surgery can help people with a certain type of advanced rectal cancer. About 128 adults with non-spreading rectal cancer will be split into two groups: one gets the drug combo, the other gets chemo alone. The goal is to see if the combo leads to more tumors completely disappearing by the time of surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.